US 11369597

I'll search for this specific patent number and related docket/litigation information.

Let me check for litigation, PTAB, and appellate docket activity.

Let me try to retrieve the actual claim text.

I'll search the litigation databases for US 11,369,597 specifically.

Let me verify whether other defendants were also sued on the '597 patent, and check for any newer filings.

Let me check for any additional Onivyde/irinotecan liposome litigations that also name the '597 patent.

Litigation Involving U.S. Patent No. 11,369,597

Search date basis: the sources below are the live litigation databases (Unified Patents case list, DrugPatentWatch, RPX Insight, ParagraphFour, the PTAB record repository, and the pleadings themselves). Building on the earlier sections of this analysis — the PTAB section already establishes that no AIA proceeding names the '597 patent — I do not repeat that here. This section covers the district-court assertion record only.

Bottom line: there is exactly one (1) known litigation involving US 11,369,597, and it is a single consolidated Hatch-Waxman action in D.N.J. against one defendant group. No other district court case, no CAFC appeal, and no PTAB proceeding names the '597 patent.

---

1. Summary table

That is the complete list. I found no second suit, no other defendant, and no appellate record naming the '597 patent.

---

2. The one case, in detail

Ipsen Biopharmaceuticals, Inc. et al. v. Conjupro Biotherapeutics, Inc., et al., D.N.J.

• Cause of action: 35 U.S.C. § 271(e)(2)(A) (artificial act of infringement) arising from Conjupro's NDA No. 218923 for an irinotecan liposome injection, 43 mg base/10 mL — a 505(b)(2) follow-on to Ipsen's Onivyde® (NDA 207793) — accompanied by a Paragraph IV certification. The propounded defendants are Conjupro (Princeton, N.J.), its parent CSPC Pharmaceutical Group Limited (Hong Kong), and CSPC Ouyi Pharmaceutical Co., Ltd. (Hebei, China).
• Filing date: April 15, 2024 (per the complaint, the ParagraphFour docket entry, and DrugPatentWatch). This is within the statutory 45-day window following Ipsen's receipt of Conjupro's notice letter (received at the latest March 7, 2024, per Conjupro's counterclaims).
• '597's specific role: Count VIII — "Infringement by Conjupro/CSPC of U.S. Patent No. 11,369,597" (¶¶114–123). The complaint attaches the '597 patent as Exhibit H and pleads the § 271(e)(2)(A) artificial-infringement count off the P-IV certification. Sources: the complaint text mirrored at https://insight.rpxcorp.com/litigation_documents/15650730 and the answer/counterclaim record at https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557313](/patent/1557313)/download-documents?artifactId=I2bC7HkAc9TKaFUINHWd_1YXZcjJIynyIOLu7Nt0ctOlk2J3c5SwMIk
• Patents asserted together with '597 in the original complaint: 8,329,213; 9,339,497; 9,364,473; 9,452,162; 9,492,442; 9,717,724; 10,980,795; and 11,369,597. (DrugPatentWatch's case page also lists 12,364,691 among the case's patents, but that patent was added by the third, consolidated complaint — see § 3.)
• Defendants' response: answer filed with affirmative defenses (non-infringement; invalidity under §§ 101, 102, 103, 112 and/or double patenting; failure to state a claim; prosecution history estoppel; equitable defenses; no injunctive relief) and counterclaims for declaratory judgment of non-infringement and invalidity as to the '597 patent. The answer expressly "den[ies] that the '597 patent was duly and legally issued." Dated September 10, 2025 for the third-complaint pleading: https://paragraphfour.com/wp-content/uploads/2024/04/njdc25cv13647A.pdf
• Outcome: None reached. No claim construction order, summary judgment, trial, or settlement naming the '597 patent was located. Counsel: Sterlington LLP (Brian V. Slater) for Ipsen; Fox Rothschild LLP (Gerard P. Norton, Paul W. Kalish) for Conjupro/CSPC.
• Independently reported parallel PTAB activity by these same defendants is directed at US 11,344,552 — not the '597 patent (IPR2025-00505, instituted 2025-08-14, with IPR2025-01531 joined). That is fully covered in the earlier PTAB section and is not a proceeding on the '597 patent.

Docket-number discrepancy (carried forward, unresolved)

Two renderings of the same case number appear across sources:

The pleading-captioned form 24-4991 (RMB)(MJS) is the most reliable, since it comes from the filed documents. The "3:" vs. "1:" prefix is a division-offset artifact. Verify on PACER before relying on either.

---

3. Related consolidated cases — these do NOT involve the '597 patent

Because they share the same docket and parties, they will appear alongside '597 in any search. Flagging explicitly so they are not mis-attributed:

Neither the '59,497 patent nor the '691 patent is the '597 patent. The '597 patent is asserted only in the April 15, 2024 complaint (Count VIII).

---

4. Negative findings — what does not exist

• No other U.S. district court action naming the '597 patent. Not against Apotex, not against Cipla, not against any Delaware-forum defendant. (Apotex's and Cipla's involvement in this patent family is real but is confined to the '552 patent IPR; Cipla's status is as an identified RPI under a 2025-05-14 Conjupro–Cipla license — see the PTAB section.)
• No CAFC appeal involving the '597 patent. Nothing to appeal: no final judgment, and no PTAB FWD on this patent.
• No PTAB proceeding on the '597 patent (restated here only for completeness; full analysis is in the earlier section).
• No ITC § 337 investigation naming the '597 patent was located.
• No foreign counterpart litigation tied to the '597 patent specifically. Google Patents' front page carries a Darts-IP "First worldwide family litigation" marker (https://patents.darts-ip.com/?family=57601636), but that is a family-level flag; the European opposition/appeal activity I could identify (e.g., T 0883/23, EP 3,337,478) belongs to the NALIRIFOX/first-line family, not a verified EP member of PCT/US2013/045495. I could not map the '597's EP counterpart and am not asserting one.

---

5. Verification gaps and flags

1. Date inconsistency — flagged, not reconciled. The task states the current date is April 26, 2026, but one retrieved source (DrugPatentWatch's case page) self-reports "Last Updated: August 3, 2026," and the authoritative patent fetch is timestamped 2026-09-28. Earlier sections of this analysis flagged the same mismatch. I report the docket facts as found and do not normalize the dates.
2. The second search hit the tool-call/step cap, so my sweep of the broader Onivyde/irinotecan-liposome litigation landscape is not exhaustive. The negative finding for "other '597 suits" is well-supported by the sources reached (Unified Patents, DrugPatentWatch's patent-specific page, RPX, ParagraphFour, the PTAB record), but treat it as a strong negative rather than a mathematical certainty given the capped search.
3. No service date confirmed. The § 315(b) one-year clock (the crux of the earlier PTAB section) runs from service of a complaint alleging infringement of '597, not from filing. I did not retrieve the service date. If you are advising a party in this case, that is the single fact to pull from PACER.
4. The complaint does not identify asserted claims or provide claim charts for the '597 patent (per the complaint-analysis source at https://ai-lab.exparte.com/case/dct/njd/1:24-cv-04991/doc/analysis/1). The infringement theory is pleaded generally off the P-IV certification and the proposed product's "intended therapeutic use." That is an infringement-contentions issue for the plaintiff.

---

6. What this means, building on the earlier sections

• The earlier sections concluded the '597 patent is substantively untested — no IPR, no FWD, no estoppel. The district-court picture confirms and reinforces that: the '597 patent's only adversarial exposure to date is a Hatch-Waxman action in which the defendants have pleaded generic §§ 101/102/103/112 defenses and DJ counterclaims without identifying specific art, and which has not reached claim construction, dispositive motions, or trial.
• The single-source assertion posture (one defendant group, one forum, one case) is consistent with the "operating-company assertion" verdict reached in the assignment-history section — Ipsen asserts the patent directly, against a follow-on filer, in its home-adjacent forum, and has not placed the '597 patent in front of the PTAB or any NPE.
• The contrast to emphasize: the '552 patent is the patent under active, instituted, multi-petitioner attack; the '597 patent is the patent that, so far, has only been filed against — and never adjudicated. Any statement that the '597 patent "survived" or "lost" a PTAB challenge is incorrect; the only PTAB activity in this estate concerns a different patent with a materially different effective filing date.

Primary sources: https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A24-cv-04991 ; https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=IPSEN+BIOPHARMACEUTICALS%2C+INC.+v.+CONJUPRO+BIOTHERAPEUTICS%2C+INC.%7C1%3A24-cv-04991 ; https://insight.rpxcorp.com/litigation_documents/15650730 ; https://paragraphfour.com/members/parryashford/activity/11735/ ; https://paragraphfour.com/wp-content/uploads/2024/04/njdc25cv13647A.pdf ; https://ai-lab.exparte.com/case/dct/njd/1:24-cv-04991/doc/analysis/1

I'll start from the canonical structured list and then verify against live sources.

The structured block reports zero AIA proceedings, but search surfaced PTAB petition documents mentioning Bayever/FOLFIRINOX. Let me pin down the actual proceeding numbers and which patent each targets.

Now I have leads: a D.N.J. case (Ipsen v. Conjupro) and CSPC-family PTAB petitions. I need the exact IPR numbers and which patents they hit.

⚠️ Important framing note before the deliverable. I hit the tool-call limit, so this section reflects (a) the canonical ODP block in my prompt and (b) the live sources I could reach before the cap. I could not pull PTAB E2E / PTAB Decisions directly. Where that leaves a gap, I say so rather than fill it.

---

Proceedings overview

Zero AIA trial proceedings are on file against US 11,369,597. The canonical structured block — sourced from the USPTO Open Data Portal — reports no IPRs, PGRs, or CBMs for this patent, and my web search surfaced no petition, institution decision, or Final Written Decision naming 11,369,597 as the challenged patent; the only PTAB activity in this molecule's patent estate is against the sibling patent US 11,344,552 (the NALIRIFOX/first-line patent), which is a different patent with a different effective filing date (see cross-reference section below). The defensive posture this gives a defendant is therefore: the '597 patent itself is untested at the PTAB, not "hardened" by a win — but it is also, for the specific defendants already sued in D.N.J., likely beyond the § 315(b) window, which means the invalidity fight against '597 is a district-court fight, not a PTAB fight. That is a materially different posture from "the patent survived two IPRs."

---

Proceedings on US 11,369,597

None. There is no proceeding to report at claim-level granularity — no institution decision, no FWD, no settlement, no appeal. I will not manufacture a docket. The absence is corroborated by two independent sources:

• The structured ODP block in this prompt: no AIA trial proceedings recorded.
• DrugPatentWatch's patent-specific litigation page for 11,369,597 (last updated 2026-06-11) lists only district court activity — a single case, filed 2024-04-15, 35:271, D. New Jersey — with no PTAB row: https://www.drugpatentwatch.com/p/litigation/patent/11369597
• DrugPatentWatch's PTAB table for the drug irinotecan hydrochloride returns exactly one challenged patent — 11,344,552 — and no entry for 11,369,597: https://www.drugpatentwatch.com/p/alphasignals/litigation/drugname/index.php?query=IRINOTECAN+HYDROCHLORIDE

Caveat: Petitions can be filed and not yet indexed. '597 issued 2022-06-28, so a PGR is time-barred (9-month window under § 321(c) closed 2023-03-28) and the § 311(c) nine-month post-grant IPR bar closed 2023-03-28 as well. Any surviving IPR would have to come from a party not barred by § 315(b). I found none; treat "none" as a well-supported negative, not a mathematical certainty.

The assertion vehicle (why '597 matters commercially)

• Case: Ipsen Biopharma Inc. v. Conjupro Biotherapeutics Inc., D.N.J.
• Docket: Google Patents / Unified Patents litigation data lists 3:24-cv-04991 (https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A24-cv-04991); the complaint-analysis source renders the same case as 1:24-cv-04991 (https://ai-lab-cl-prod.azurewebsites.net/case/dct/njd/1:24-cv-04991/doc/analysis/1). Flagging the discrepancy rather than picking one — verify the division prefix on the live docket.
• Filed: 2024-04-15 (per DrugPatentWatch).
• Accused product: Conjupro's irinotecan liposome injection, NDA No. 218923 — a generic version of Onivyde.
• '597's role in the suit: the newest asserted family member; the complaint pleads it against the proposed product's intended therapeutic use but, per the complaint-analysis source, does not identify asserted claims or provide claim charts.

---

Cross-reference: sibling-patent PTAB proceedings (NOT proceedings on '597)

These are included because they are the nearest thing to PTAB intelligence on this patent family, and because they will surface in any freedom-to-operate review. They do not invalidate, narrow, or estop anything with respect to US 11,369,597.

IPR2025-00505 — CSPC Pharmaceutical Group Ltd., CSPC Ouyi Pharmaceutical Co., Ltd. & Conjupro Biotherapeutics, Inc. v. Ipsen Biopharm Ltd. (challenged patent: US 11,344,552 — not '597)

• Type: Inter Partes Review
• Filed: 2025-01-17 (accorded 2025-01-17)
• Status: Trial instituted — institution granted 2025-08-14. Sources: https://ai-lab.exparte.com/case/ptab/IPR2025-00505/cspc-pharmaceutical-group-ltd-v-ipsen-biopharm-ltd ; https://www.drugpatentwatch.com/p/alphasignals/litigation/patent/11344552
• Judge panel: Jeffrey N. Fredman, Timothy G. Majors, Zhenyu Yang (same source).
• Petition grounds (as described in the petition/record): challenged claims 1–15. Ground 1 — claims 1, 3–6, 8–14 obvious over Conroy, Conroy Protocol, Conroy Appendix, and Mahaseth in combination with Bayever, Saif, Ko, and Cantore. Ground 2 — claims 2, 7, 15 over Ground 1 in further combination with Masi and Ginocchi. Statutory basis § 103. (Summary via https://ai-lab.exparte.com/case/ptab/IPR2025-00505/doc/1017)
• Institution decision: instituted 2025-08-14. Ipsen filed a Request for Discretionary Denial invoking the Director's March 26, 2025 workload-management memorandum and § 325(d) (same Conroy + Bayever lead references the examiner considered) — the Director declined Ipsen's discretionary-denial push, and trial was instituted. Petitioners' updated mandatory notices (2025-07-18) name Cipla USA Inc. as an RPI over Ipsen's objection, disclosing a 2025-05-14 exclusive license from Conjupro to Cipla: https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1557313](/patent/1557313)/download-documents
• Final Written Decision: none located as of the sources I could reach. Statutory § 316(a)(11) deadline from the 2025-08-14 institution is 2026-08-14 (extendable to 2027-02-14 for good cause) — which, against today's date (2026-09-28), means an FWD may already exist that my capped search did not surface. Verify directly on PTAB E2E before relying on the absence.
• Settlement: no termination-by-settlement located.
• Appeal: none (no FWD to appeal).
• Defensive value: not attributable to '597. For the '552 patent, this is the live invalidity vehicle — and the joinder below means at least two generic filers are pooling resources behind one trial.

IPR2025-01531 — Apotex, Inc. v. Ipsen Biopharm Ltd. (challenged patent: US 11,344,552 — not '597)

• Type: Inter Partes Review, resolved by joinder into IPR2025-00505
• Filed: 2025-09-12
• Status: Joinder granted 2026-03-12 (Paper 16) — Apotex joined as a petitioner in IPR2025-00505. Apotex represented that its petition and supporting declaration were "substantially identical" to those in IPR2025-00505 and that it would be a "silent understudy." Ipsen withdrew its opposition to joinder. Source: NYIPLA PTAB Committee materials (March 2026), https://www.nyipla.org/images/nyipla/Programs/2026/March17PTABMeeting/March%20PTAB%20Committee%20Meeting_.pdf — note this document is an OCR scan; the statute it recites as "§ 151(e)" is plainly 35 U.S.C. § 315(c), and I am correcting that as an OCR artifact, not quoting it.
• Judge panel (joinder decision): Zhenyu Yang, Tawen Chang, Timothy G. Majors.
• Settlement / Appeal: none located.
• Defensive value: not attributable to '597. Its practical effect is that Apotex's planned Ground 3 (Carnevale and Dean — per Ipsen's Apotex POPR: https://paragraphfour.com/wp-content/uploads/2024/04/ipr25-1531PR.pdf) gets folded into the CSPC trial. Again: this is the '552 patent.

Foreign counterpart activity (context only — not an AIA proceeding)

Ipsen has taken appellate hits and wins on the European side of the liposomal-irinotecan pancreatic franchise: T 0883/23 (Board 3.3.07, decision 2025-09-26) concerning EP 3,337,478 — "Drug combination comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin for treating metastatic pancreatic cancer," opponents Sandoz AG and Generics [UK] Ltd. The decision's keyword block records priority – same invention (no) and inventive step – (yes), with late-filed evidence not admitted: https://www.epo.org/boards-of-appeal/decisions/t230883eu1 . I did not obtain the order of the decision, so do not treat the priority/inventive-step findings as a final disposition without checking. Note this is the NALIRIFOX patent family, not the '597 family's EP member — I could not verify which EP number maps to PCT/US2013/045495 and am not asserting one.

---

Strategic summary

Claim-level status of '597. Every claim of US 11,369,597 is UNTESTED. Nothing is canceled; nothing is sustained in an adversarial forum. The Google Patents front-page "Family has litigation" entries (a D.N.J. case and a Darts-IP worldwide-family litigation record) reflect district court assertion, not PTAB adjudication. Anyone who tells you "claims 1–5 have been canceled" about this patent is confusing it with a different family member.

Estoppel landscape for a current defendant. § 315(e)(2) estoppel attaches only to parties to a proceeding on this patent. Because there is no proceeding on '597, no estoppel exists against anyone as to '597 — the entire prior-art field remains available. That cuts both ways: it also means the CSPC/Apotex investment in IPR2025-00505 buys them nothing at the PTAB on '597. Two timing points follow, and they are the crux of the defensive posture:

1. § 315(b) may already bar the named D.N.J. defendants from petitioning on '597. '597 was asserted in a complaint filed 2024-04-15. One year from service of a complaint alleging infringement is the outer limit for an IPR petition. If service occurred in or around April 2024, the window for Conjupro (and any co-defendants properly served) closed in or around April 2025 — before the '552 IPRs were even filed. I could not confirm the service date, and the bar runs from service, not filing — verify this against the docket before advising. If it holds, it is a significant structural fact: the patent owner gets to litigate '597 in a forum where invalidity must be proved by clear and convincing evidence, not by a preponderance.
2. New, unserved challengers are not barred. A party that has never been served with a complaint alleging infringement of '597 can still petition — subject only to § 315(a) (no prior DJ action) and § 325(d) discretion. The § 311(c) post-grant window closed 2023-03-28; that restriction is gone.

The '552 IPRs are not a transplantable roadmap to '597 — and the reason is a priority-date trap. The linchpin reference in IPR2025-00505 is "Bayever" = WO 2013/188586 (Ex. 1006). That document is the publication of PCT/US2013/045495, filed 2013-06-12 — i.e., it is the '597 family's own PCT publication, published 2013-12-19. The '597 patent claims priority to 2012-06-13 / 2013-06-12. A publication dated 2013-12-19 post-dates that priority and therefore cannot be prior art against '597 (whether it also fails the "same inventors / commonly owned" disqualification is a separate question you should brief). The '552 patent, by contrast, has a much later effective filing date — Ipsen's own Apotex POPR states the '552 claims have an effective filing date of 2015-08-21 — which is precisely why Bayever works as art there and will not work here. Any invalidity theory on '597 must be rebuilt from the pre-2012/2013 art, not copied from the '552 petition. Expect the Conroy/Conroy Protocol/Conroy Appendix/Mahaseth/Masi/Ginocchi/Ko/Cantore/Saif set to be re-examined for which members actually pre-date the '597 priority — Ko (2013 Br. J. Cancer) and Saif (2014 J. Pancreas) are themselves suspect on date.

Pattern signals. The petitioner chain is a defensive-consortium pattern among generic filers, not a defensive aggregator: CSPC + Conjupro (petitioner and D.N.J. defendant), with Cipla identified as an RPI via a 2025-05-14 license, and Apotex joining with a "substantially identical" petition and a silent-understudy role. Unified Patents appears only as a litigation-data source in the Google Patents page — there is no evidence Unified is a party. The patent owner is litigating hard on discretion: Ipsen filed a Request for Discretionary Denial, a preliminary response, a POPR opposing Apotex, and a (denied) request to strike new evidence — a § 325(d) + Director-discretion playbook, not a merits-first playbook.

---

Recommended next steps

1. Verify the negative directly, today. Open PTAB E2E for US 11,369,597 (Petition/Patent search) and confirm no proceeding exists. Confirm in the same pass whether an FWD has issued in IPR2025-00505 — its statutory deadline was 2026-08-14, which has passed as of today, and my capped search did not reach it. If an FWD exists and canceled claims of the '552 patent, that is a signpost, not a judgment, about '597: useful for framing obviousness for the '597 art, worthless as estoppel or res judicata.
2. Pull the docket in Ipsen Biopharma Inc. v. Conjupro Biotherapeutics Inc. and fix the service date for '597. Confirm the docket number (3:24-cv-04991 vs. 1:24-cv-04991) while you are at it. The § 315(b) analysis above turns entirely on the '597-specific service date, and it is the single most decision-relevant fact in this section. If you are a defendant served in 2024, assume you are PTAB-barred on '597 and build your invalidity case for the district court; if you are a new filer not yet served, you may still be able to petition.
3. Do not import the '552 grounds. Rebuild the '597 obviousness case from scratch against the 2013-06-12 priority, and specifically test whether each Wainwright-style combination reference pre-dates it. Get the provisional filings (61/659,211, 2012-06-13; 61/784,382, 2013-03-14) and the PCT/US2013/045495 disclosure to see what the family actually possessed on day one — that is what governs whether the intervening art sticks.
4. If you are defending on induced infringement, note that the complaint-analysis source says the complaint asserts no claims and provides no claim charts for '597. Whatever the merits, that is a discovery and infringement-contentions problem for the plaintiff, and worth a pointed interrogatory.
5. If you are a new entrant considering an IPR on '597, budget for § 325(d): the examiner rejected repeatedly over the same art, and Ipsen will run the same "material error / no Examiner error" fight that failed to stop institution in IPR2025-00505 (institution 2025-08-14). The discretionary-denial record from IPR2025-00505 is public and will be replayed against you — read Ipsen's DDB (Petition ID 1557313) first.

I'll research the assignment record for US 11,369,597. Let me run several targeted searches.

Let me dig deeper into the specific assignment records and correspondents.

I was able to retrieve the corporate-transaction context and family-level assignment data, but the live USPTO Assignment Center record for the '597 patent itself did not surface in searchable form. Below I distinguish what is documented from what I could not verify.

---

Inventors

All seven are named in the Google Patents legal-events record as assignors to Merrimack Pharmaceuticals, Inc. on the inventor→company assignment, which corroborates Merrimack as the common employer. This is a single-employer inventor group (a company pipeline patent, not a university or multi-party collaboration). Clet Niyikiza was a Merrimack co-founder/executive and Eliel Bayever served in a senior clinical role at Merrimack — consistent with a company-originated invention, though I did not independently verify each individual's title.

Departure pattern: I found no per-inventor employment-end data, so I cannot confirm or refute the "all inventors departed within 12 months" red flag. Note as context, however, that Ipsen's own deal materials state the April 2017 transaction included the "transfer of over 100 employees" (commercial + manufacturing) from Merrimack to Ipsen, and the priority filing predates the sale by ~5 years. There is no evidence the inventors departed on a fire-sale timeline.

---

Original assignee

As printed/indexed on the issued patent: Ipsen Biopharm Ltd. (Google Patents lists both "Original Assignee" and "Current Assignee" as Ipsen Biopharm Ltd.)

Historically (the true original owner of the invention): Merrimack Pharmaceuticals, Inc. (Cambridge, MA; NASDAQ: MACK) — the entity to which all seven inventors assigned.

• Product shipped: Yes. Merrimack obtained FDA approval of Onivyde® (irinotecan liposome injection, MM-398) in October 2015 for metastatic pancreatic adenocarcinoma after gemcitabine failure; the '597 patent is listed in the Orange Book for NDA 207793 (use code U-1848; patent expiry 2033-06-12).
• Primary line of business: oncology drug development/commercialization (biopharma).
• Current status: Merrimack ceased independent commercial operations after divesting its assets. It sold the Onivyde/MM-398 oncology assets to Ipsen on April 3, 2017 for $575M at closing plus up to $450M in contingent milestones (announced January 9, 2017; Merrimack shareholder-approved). It later sold anti-HER3 programs to Elevation Oncology (2019) and nanoliposome assets to Celator (2020), operating essentially as a milestone-rights holder. No bankruptcy proceeding is reflected in the record — the divestitures were strategic, not a Chapter 7/11 fire-sale.
• Ipsen Biopharm Ltd. (UK; part of Ipsen S.A., Euronext: IPN) is a large operating specialty-pharma company and remains the current owner/assaerter.

---

Assignment timeline

⚠️ Verification caveat: The USPTO Assignment Center record for US 11,369,597 did not surface in my searches, so I could not retrieve the '597 patent's own reel/frame numbers or its recorded correspondent. The reel/frame references below were surfaced from a sibling Merrimack→Ipsen family patent (US 8,658,203) and reflect the same portfolio-level transaction; the '597 patent was filed as a continuation and transferred as part of the same asset sale. Treat the reel/frame attribution to the '597 patent as probable, not confirmed.

• ~2012–2013 (executed) / recorded 2021-05-10 (per Google Patents legal events for this patent)

  • Conveyance: Assignment of interest ("ASSIGNMENT OF INTEREST" / ASSIGNMENT OF ASSIGNORS INTEREST)
  • Assignor: Kim, Jaeyeon; Niyikiza, Clet; Moyo, Victor; Bayever, Eliel; Fitzgerald, Jonathan Basil; Dhindsa, Navreet; Laivins, Peter (the seven inventors)
  • Assignee: Merrimack Pharmaceuticals, Inc.
  • Correspondent: Not retrievable from available records — flag as unknown.
  • Context: Original inventor-to-employer assignment; routine, not an NPE event.

• 2017-04-03 (executed) / recorded 2021-05-10

  • Conveyance: Assignment (corporate asset-sale transfer of the oncology portfolio)
  • Assignor: Merrimack Pharmaceuticals, Inc.
  • Assignee: Ipsen Biopharm Ltd.
  • Correspondent: Not retrievable — flag as unknown. (I could not confirm whether the recording attorney differs across the two reel entries below; that would be the key repeat-correspondent check if you pull the images.)
  • Context: Acquisition — Merrimack's sale of Onivyde/MM-398 to Ipsen; two related reel entries appear in the family (assignee styled "Ipsen Biopharm Ltd., United Kingdom" at Reel 042377/0696, and "Ipsen Biopharm Ltd., Great Britain" at Reel 042522/0334), both from Merrimack, both effective 2017-04-03. These are two batches of one corporate transfer, not a chain of successive owners.

No further recorded assignments were found after the 2017 Merrimack→Ipsen transfer. There is no post-issuance transfer to a licensing entity, NPE, or defensive aggregator.

Discrepancy to flag: Google Patents shows both assignments with a 2021-05-10 recordation date, yet the Merrimack→Ipsen execution is 2017-04-03 (and the corresponding reels are 0423xx/0425xx, which are 2017-era reels). The 2021-05-10 figure is most likely a data-ingestion/late-recordation artifact rather than the true recording date for the 2017 transfer. Confirm via the Assignment Center record images.

---

Timeline diagram

timeline
    title Ownership of US 11369597
    2012 : Priority application filed
    2013 : PCT filed by Merrimack
    2015 : Onivyde approved by FDA
    2017 : Merrimack sells portfolio to Ipsen
         : Executed 3 April 2017
    2018 : Continuation filed as Ipsen
    2021 : Assignments recorded at USPTO
    2022 : Patent issued on 28 June
    2024 : Ipsen sues Conjupro and CSPC

---

NPE / troll-pattern signals

---

Verdict

Operating-company assertion.

The ownership chain is a clean two-step corporate sequence: the seven Merrimack inventors assigned to Merrimack Pharmaceuticals, Inc., which transferred the oncology portfolio to Ipsen Biopharm Ltd. on 2017-04-03 (reels 042377/0696 and 042522/0334 in the family record). Ipsen is an operating pharma that ships Onivyde® (Orange-Book-listed for NDA 207793, '597 expiry 2033-06-12) and asserted the '597 patent directly against generic competitors Conjupro/CSPC in the 2024 Hatch-Waxman action — the hallmark of genuine operating-company assertion, with zero shell-entity, cascading-transfer, pre-litigation-transfer, bankruptcy, or known-asserter signals. The only open item is the recording correspondent (signal 3), which I could not retrieve; if you pull the reel images, verifying that field is the one remaining check that could theoretically change this call.

Verification: USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search by patent number 11369597); mirror index at https://assignment.uspto.gov/patent/index.html. Family/litigation cross-reference: Google Patents legal events for US11369597B2 (https://patents.google.com/patent/US11369597B2/en).

I'll research the patent's citation records and prior art. Let me run several searches.

Let me look specifically at the patent's citation records and family.

Let me try to retrieve the patent's citation tables directly.

Prior-Art Analysis — U.S. Patent No. 11,369,597 B2

Important scope/limitation note (read first)

The task asks me to walk through each patent citation on the face of U.S. 11,369,597 ("the '597 patent"). I must be transparent: I was unable to retrieve the examiner's citation tables (the Form PTO-892 "References Cited" / "Patent Citations" sections) for the '597 patent from the sources I could access. Google Patents returns the '597 record in search snippets, but its citation tables did not render in the retrievable text, and the authoritative patent text supplied to me for this matter contains the specification, claims, abstract and family data — not the front-page reference lists. Justia/FreePatentsOnline mirrors of sibling family members likewise returned specification text rather than the citation tables.

Under the operating rules I will not invent patent numbers or citation counts. Accordingly, below I (a) enumerate the references I can ground in the record, (b) separate patent documents from non-patent literature, (c) mark confidence for each, and (d) map each to the § 102 analysis. Where I cannot confirm a reference was actually cited on the '597 face, I say so.

---

1. Verified bibliographic anchor data for the '597 patent

Priority/§ 102 regime. Because the earliest priority is 2012-06-13, pre-AIA § 102/103 presumptively governs, subject to the wrinkle that the '597 descends through a continuation-in-part (the '724 patent added NAPOLI-1 clinical data). Any claim element whose written-description support exists only in the CIP matter takes a later effective date (≈2016). This matters: the NAPOLI-1 regimen limitations (80 mg/m² q2w + 5-FU/LV; UGT1A1*28 dose reduction) are exactly the elements whose priority date is most contestable, and they are the elements the prior art below attacks.

---

2. Patent documents (references cited "by or against" the family)

2a. References expressly identified in the '597 specification (highest confidence)

These are named in the authoritative patent text I was given, so they are verifiable:

2b. Patent documents I could not verify are cited on the '597 face (low confidence — flagged, not asserted)

I located no reliable rendering of the '597's examiner-cited patent list. I therefore do not list specific U.S./foreign patent numbers as "cited on the '597" because I cannot ground them. (Search attempts returned citation tables for unrelated patents — e.g., EP 2925134, WO 2020/172395, WO 2023/235278 — which must not be mistaken for the '597's citations.)

---

3. Non-patent literature (references grounded in the family record)

3a. Confirmed in family prosecution (high confidence)

3b. Background art recited in the '597 specification (grounded in the text, high confidence)

These are named in the patent as the state of the art, so they are verifiable as described (I have not independently confirmed each full citation):

---

4. § 102 mapping — which claims each reference can actually anticipate

Caveat: I mapped against the claim subject matter as disclosed in the '597's Summary/Definitions (the q3w 120 mg/m² monotherapy with 80 mg/m² UGT1A1*28 reduction; the q2w co-administration of liposomal irinotecan + 5-FU + LV at 80/60 mg/m²; 5-FU 2400 mg/m²; LV 200/400 mg/m²; and the ordered 90/30/46-hour infusion claims). I could not retrieve the literal granted claim set, so this is a subject-matter mapping, not a claim-number-specific ruling.

---

5. The three references I judge "most relevant" (ranked)

1. WO 2005/107712 A2 (liposome drug-delivery; MM-398 composition) — the indispensable § 102/§ 103 base reference. Grounded: expressly incorporated by reference in the '597 spec.
2. Hoskins et al., JNCI 2007 (UGT1A1*28 genotype + irinotecan dose) — the key § 102(b) reference against the genotype dose-reduction limitations. Grounded: cited in the sibling family (US 9,452,162) record.
3. NAPOLI-1 / Wang-Gillam et al. — the reference that the patent's own specification describes in full; its § 102 status turns on whether the CIP-added limitations keep the 2012 priority date.

---

6. What I could not determine (explicit)

• The complete examiner-cited "Patent Citations" list for the '597 face — not retrieved. I will not enumerate specific patent numbers as "cited" without grounding, per the no-fabrication rule.
• The literal granted claim set (claim numbers and exact scope) — the supplied authoritative text ends mid-Summary; I mapped to the disclosed subject matter rather than to numbered claims.
• Whether the family members (US 9,452,162 / 9,717,724 / 10,980,795) should be treated as § 102 art in the Conjupro litigation — they are common-family/common-owner and are presumptively not § 102 art to the '597, but a defendant may argue a CIP-added disclosure with a different inventive entity. I did not verify inventive-entity differences.

Recommended next step to close the gap: pull the '597's Form PTO-892 / "References Cited" from USPTO PatentCenter (application 16/012,372) or the Google Patents "Patent Citations" tab, then I can convert this mapping into a claim-number-exact § 102 table.

Sources: patents.google.com/patent/US11369597B2/en (authoritative text supplied); patents.google.com/patent/US9717724 and /US20190117644A1 (family/continuity); patents.justia.com/patent/9452162 (family; NPL "Hoskins…" entry); pharmacompass.com irinotecan-hydrochloride page (expiry 2033-06-12). Citation tables for EP 2925134 / WO 2020/172395 / WO 2023/235278 appeared in searches and are unrelated to the '597 — recorded here only to warn against mis-attribution.

I'll begin by locating the actual prior-art references cited against this patent and the specific claim language, since the provided page content does not include a populated "References Cited" / "Prior Art" section (only the front-page Prior art keywords: irinotecan, patients, dose, leucovorin, treatment). Let me pull what the record shows.

I have the issued claim 1. Now let me pull the full claim set and the patent's face-level "References Cited" list, plus the EPO opposition art that has been asserted against family members.

Obviousness Analysis — U.S. Patent No. 11,369,597 under 35 U.S.C. § 103

Analysis date: April 26, 2026 (per task instruction; note the system timestamp on the fetched patent page reads 2026-09-28 — a discrepancy I flag rather than reconcile).

---

0. Threshold note on the "Prior Art section of this page"

The page as supplied to me does not contain a populated prior-art results table. What the Google Patents record actually provides under "Prior Art" is only:

There is no "References Cited" list, no Cited-By list, and no Similar-Documents list in the text I was given. That is a material gap, because the entire §103 question turns on those references. To avoid fabricating, I reconstructed the cited art from two verifiable sources: (i) the "References Cited — Other Publications" block on the face of this patent (retrieved from the patent's own PDF, patentimages.storage.googleapis.com/75/d3/94/42c97afbb783cc/US11369597.pdf), and (ii) the D-reference sets from the Sandoz AG and Generics [UK] EPO oppositions against sibling family members (EP3337467 / EP3337478), which are the art parties have actually litigated.

Contradiction flagged: the previously generated "Patent summary" section of this analysis is essentially a placeholder (only "I'll search…" text). It supplies no content to build on. The "Litigation summary" section is substantive and I rely on it below; it is consistent with what I independently retrieved.

---

1. The claim to be analyzed

Claim 1 (per DrugPatentWatch's reproduction of the issued text) recites:

A method of treating metastatic adenocarcinoma of the pancreas in a human patient who has previously been treated with the antineoplastic agent gemcitabine, comprising intravenously administering to the patient once every two weeks, an antineoplastic therapy consisting of:
(a) irinotecan sucrose octasulfate salt liposome injection in an amount providing the equivalent of 70 mg/m² of irinotecan free base … wherein, following administration in patients, the injection has a mean total SN-38 terminal elimination half-life in the plasma of 67.8 ± 44.5 hours;
(b) 200 mg/m² (l)-leucovorin or 400 mg/m² (l+d) racemic leucovorin; and
(c) 2,400 mg/m² 5-fluorouracil.

Dependent claims add only: infusion durations (cl. 2: 90 min / 30 min / 46 h), gemcitabine progression (cl. 3), three pharmacokinetic ("PK") parameters (cll. 4–6), 400 mg/m² racemic LV (cl. 7), anti-emetic premedication (cl. 8), and liposome-composition/size limitations (cll. 9–11: MPEG-2000-DSPE; DSPC:Chol:PEG-PE = 3:2:0.015; 80–140 nm).

(Source: drugpatentwatch.com/p/patent-claims/11369597.)

---

2. The controlling date question — and why it drives the whole analysis

The patent's nominal chain is: US 16/012,372 (filed 2018-06-19) ← 15/664,930 (2017-07-31) ← 15/241,128 (2016-08-19, now US 9,717,724) ← CIP of 14/406,776 (now US 9,452,162) ← §371 of PCT/US2013/045495 (2013-06-12) ← prov. 61/659,211 (2012-06-13) and 61/784,382 (2013-03-14). Google Patents records the "prior art date"/priority as 2012-06-13.

But claim 1's PK limitation is almost certainly not supported by the 2012 provisional. The value "mean total SN-38 terminal elimination half-life … 67.8 ± 44.5 hours" is a Table 3 / population-PK value generated from the later Phase 1–3 program (MM-398 80 mg/m² salt, "353 patients … population pharmacokinetic analysis," per the specification). A POSITA cannot derive that number, or possession of a 70 mg/m²-free-base q2w regimen defined by that number, from a June-2012 disclosure.

Consequences, and this is the pivotal §103 point:

• If claim 1 gets 2012-06-13, the pre-date art is Chen 2010 (PEP0203), the PharmaEngine "PEP02" webpage (2011-08-04), Drummond 2006, and the FOLFIRI/FOLFIRINOX literature.
• If claim 1 gets only 2016-08-19 (the '128 CIP) or 2017/2018, then the applicant's own prior art-adjacent publications become §102(a)(1) prior art, including:
  • von Hoff et al., Ann Oncol. 25(Suppl 2):ii105 (2014) — the NAPOLI-1 abstract, which is printed on the face of the '597 patent itself as a cited reference and which reports the exact regimen;
  • WO 2013/188586 A1 (the family's own PCT, published 2013-12-19);
  • US 9,717,724 and US 9,452,162 (sibling patents in the same chain);
  • the Onivyde (MM-398) package insert, rev. Oct. 22, 2015.

Under Dynamic Drinkware/In re NTP practice, a claim is entitled to priority only if the priority document provides §112 support for that claim. Because claim 1 is drafted around a later-generated PK figure, the priority claim is vulnerable, and the effective date likely slides to a point after the NAPOLI-1 disclosure. This is precisely the logic the EPO Board applied to the sibling case discussed at epo.org/legal/case-law/2025/clr_ii_d_4_6.html (finding the priority document (P1) disclosed only a conditional proposal for a dose-escalation study, not the tolerable, claimed dose combination — so priority failed and the later-published data could not be relied on as disclosing the claimed invention). The same reasoning applies a fortiori here, where the claim recites a numeric PK property absent from the 2012 filing.

---

3. The prior art relied upon

(Sources: the '597 face "Other Publications" list at patentimages.storage.googleapis.com/75/d3/94/42c97afbb783cc/US11369597.pdf; the Sandoz/Generics-UK opposition D-sets reproduced at patents.google.com/patent/US11344552 and patents.justia.com/patent/11071726.)

---

4. POSITA and the legal framework

POSITA: a physician-scientist or clinical pharmacologist with an M.D. or Ph.D. and ≥3–5 years' experience in medical oncology, specifically in the development of topoisomerase-I inhibitor and 5-FU/leucovorin regimens for gastrointestinal cancers, working with a formulation scientist. This person is fully conversant with FOLFIRI/FOLFOX/FOLFIRINOX, with Camptosar®'s label PK, and with the PEGylated-liposome platform (Doxil, CPX-1).

Framework: Graham v. John Deere; KSR Int'l v. Teleflex (predictable combinations of known elements, "finite number of identified, predictable solutions," design incentives); In re Montgomery / In re Kao (recited pharmacokinetic parameters are patentable only if they distinguish over the prior art); and the inherent-characteristics line (a newly discovered property of a known composition or regimen does not confer patentability).

---

5. Ground A — the simplest and strongest: D-8 von Hoff (NAPOLI-1) ± D-6/D-7/D-9

The mapping is almost literal. D-8 discloses, in a human trial, treatment of metastatic pancreatic cancer progressed on or following gemcitabine-based therapy with:

• nal-IRI 80 mg/m² (salt) = 70 mg/m² irinotecan free base, IV, q2w — the claim's element (a) dose and schedule;
• leucovorin 400 mg/m² — element (b); and
• 5-FU 2,400 mg/m² — element (c).

MM-398/nal-IRI is by definition irinotecan sucrose octasulfate encapsulated in liposomes (D-3, D-2), so the "comprising irinotecan sucrose octasulfate encapsulated in liposomes" clause is met.

The only unmapped element is the lone "wherein" clause: "mean total SN-38 terminal elimination half-life … 67.8 ± 44.5 hours."

That clause cannot carry patentability, for three reasons:

1. It is an inherent property of the prior-art product. A given liposomal irinotecan formulation (fixed DSPC:Chol:PEG-PE 3:2, ~100 nm, SOS-trapped) necessarily produces a fixed total-SN-38 half-life in a patient population. D-3 and D-7 already characterized MM-398's extended circulation and SN-38 disposition; D-9's label tabulates it. Where a claim recites a property, and the prior art discloses the thing having that property, the claim is anticipated — and a fortiori obvious. In re Kao does not help the patentee, because the recited numerical window is broad (±44.5 h, i.e., a range of ~23–112 h) and overlaps the ordinary-variability band of any prior-reported MM-398 PK.
2. It is a "whereby"-type property of administration, not a step. The claim's active steps are IV dosing of three agents q2w; the half-life is a result observed "following administration in patients." A property resulting from an otherwise-disclosed process does not render the process nonobvious.
3. It is a routine measurement. Once D-8 tells a POSITA to run the regimen, generating a population PK table for total SN-38 is the most predictable, indeed obligatory, of Phase 3 activities.

Motivation / expectation of success: D-8 is the motivation — it reports the regimen works (OS benefit vs. 5-FU/LV) with a manageable safety profile. Nothing else is needed.

Conclusion (Ground A): Claims 1–3 and 7 are obvious over D-8 alone (and would be anticipated but for the PK clauses); claims 4–6, 9–11 obvious over D-8 in view of D-3/D-7/D-9.

---

6. Ground B — with a 2012 priority date: D-1 + D-3 + D-4 (+D-2, D-10)

If the patentee successfully defends 2012-06-13, the analysis still fails, using only pre-date art:

• D-4 Conroy (2011) establishes that irinotecan/LV 400/5-FU 2400-over-46-h is an effective regimen in metastatic pancreatic cancer and, by its own dose-intensity data, that the irinotecan component is the dose-limiting/most-important element.
• D-1 Chen (2010) discloses that PEP02 (liposomal irinotecan) can be combined with weekly 5-FU/LV in advanced solid tumors — i.e., the combination, in humans, including these agents.
• D-3 Drummond (2006) discloses the MM-398 liposome: SOS-trapped, DSPC/cholesterol/PEG-PE, ~100 nm, long-circulating, with high intratumoral irinotecan→SN-38 conversion and reduced toxicity versus free CPT-11.
• D-2 PharmaEngine (2011) discloses the clinical-stage PEP02 product and its tolerability.
• D-5 Mahaseth (2013) shows that reducing the irinotecan backbone dose to control toxicity is a routine, expected clinical adjustment (motivating 80 mg/m² salt / 70 mg/m² free base rather than a full FOLFIRI irinotecan dose).

Motivation to combine (KSR-satisfying): The art presents a finite, identified, predictable solution set. FOLFIRI/FOLFIRINOX is the standard irinotecan-based pancreatic regimen; liposomal encapsulation of a cytotoxic is the established platform for widening the therapeutic index (Doxil, CPX-1, and D-3's own MM-398); PEP02 had already been given with 5-FU/LV in humans (D-1). Replacing free irinotecan with the long-circulating liposomal form, at the previously-tolerated 80 mg/m² salt (≈70 mg/m² base) level, on a q2w schedule, with the FOLFIRI LV/5-FU doses, is an optimization a POSITA would pursue with a reasonable expectation of success — D-3 supplies the mechanism (prolonged exposure, enhanced permeability/retention, TAM-mediated intratumoral bioactivation) and D-1 supplies the clinical feasibility.

Doses as obvious parameter selections: LV 400 mg/m² and 5-FU 2,400 mg/m² over 46 h are literally the FOLFIRI/FOLFIRINOX parameters (D-4). The 200 mg/m² (l)-form alternative is the recognized half-dose equivalent of the 400 mg/m² racemate — a mere dose-expression equivalence the specification itself concedes ("200 mg/m² … (l) enantiomer … and 400 mg/m² … (l+d) racemate contain equivalent amounts").

---

7. Ground C — applicant's own earlier publications (§102(a)(1))

If the effective date is the 2016/2017/2018 filing rather than 2012, then:

• WO 2013/188586 A1 (published 2013-12-19) — the family's own PCT — discloses the claimed regimen, including the 80 mg/m² salt / 60 mg/m² reduced-start UGT1A1*28 dosing and the LV/5-FU doses. A printed publication published more than one year before the 2016 CIP is §102(a)(1) art against that CIP, priority notwithstanding, if priority fails. This is the sharpest sword, and it is a self-collision.
• US 9,717,724 / US 9,452,162 — sibling patents issuing 2016 and 2017, claiming substantially the same MM-398 + 5-FU/LV method. Even on a 2012 priority date, these raise obviousness-type double patenting (OTDP) — a judicially created non-statutory obviousness extension of §103. Given the six near-identical patents in this chain (9,339,497; 9,364,473; 9,452,162; 9,492,442; 9,717,724; 10,980,795; and now the '597), OTDP is likely the most economical invalidity theory and one the patentee cannot cure with an obviousness-type terminal disclaimer if the claims are not patentably distinct.
• D-9 Onivyde label (Oct. 22, 2015) — the approved product labeling for the very regimen. Post-2015 art is fatal if priority is lost.

---

8. The dependent claims

None of the dependent claims adds an element that is not either expressly in the art or an inherent/routine property of the disclosed product.

---

9. Rebuttal of the likely secondary-consideration arguments

• "Therapeutic synergy" — the specification itself defines synergy by the log₁₀ cell-kill metric and asserts superadditivity. But a bare assertion, without head-to-head combination-index data against each single agent at its optimum dose, does not rebut a prima facie case; and D-8's own OS data already report the combination benefit.
• Unexpected results — the patentee will point to the NAPOLI-1 OS benefit. But that benefit is in the prior art it helped create (D-8) and, in any event, an efficacy result achieved by following a reference's teaching is expected, not unexpected.
• Long-felt need / commercial success (Onivyde®) — the nexus is weak: Onivyde's success flows from the PEP02 formulation (D-3/D-10) and from the NAPOLI-1 clinical program, both predating or independent of the claim's only distinguishing feature (the PK "wherein" clause and the specific three-drug q2w dose set, which the label and NAPOLI-1 abstract already taught).
• "Consisting of" closure — the closed transition is used to exclude oxaliplatin (contrast the sibling FOLFIRINOX/nal-IRIFOX patents, e.g., US 11,344,552, targeted by IPR2025-00505). Excluding an optional fourth agent is a narrowing design choice with no unexpected effect on the art of record.

---

10. Bottom line

The claims of the '597 patent are, on this record, prima facie obvious under §103: every active step (drug, liposomal form, dose, schedule, sequence, patient population) is disclosed in the pre-2016/2018 art — much of it on the patent's own face — and the sole distinguishing features are inherent pharmacokinetic properties of a known formulation (or its predictable characterization), an equivalence the specification concedes, and dose selections lifted directly from FOLFIRI/FOLFIRINOX and the NAPOLI-1 protocol. The KSR factors (finite predictable solution set, established substitution of liposomal for free cytotoxic, explicit clinical precedent in D-1/D-6/D-8) supply the motivation and the reasonable expectation of success.

---

11. Caveats — what I could not verify

1. The "Prior Art section" of the supplied page contains no prior-art results, only keywords. My reference set is reconstructed from the patent's face and the EPO opposition D-sets; I could not confirm that these are the exact references the USPTO cited against this application's claims during prosecution, nor whether any IDS/102 reference-specific rejections were made. Confirm via the file wrapper (USPTO PatentCenter for 16/012,372).
2. The effective filing date for claim 1 is unresolved and is outcome-determinative. I have argued from the specification and from the EPO Board's sibling-case reasoning; I have not seen the provisional 61/659,211 text or a court/PTAB ruling on priority for the '597 claims. This must be nailed down before any §103 opinion is final.
3. Defendants' pleaded invalidity for the '597 patent is generic. The Answer/affirmative defenses (14th–16th Defenses) invoke "§§ 101, 102, 103 and/or 112" without identifying specific art (see the D.N.J. filings at ptacts.uspto.gov and paragraphfour.com). The only identifiable obviousness content I found is in IPR2025-00505, which is against U.S. 11,344,552 (the nal-IRIFOX patent), not the '597 patent — so I caution against importing that IPR's grounds onto the '597. I found no IPR, PGR, or Federal Circuit appeal directed at 11,369,597.
4. Docket-number discrepancy (carried forward from the prior section): Google Patents states 3:24-cv-04991; the complaints/dockets state 1:24-cv-04991 and 24-4991 (RMB)(MJS). Reported as found; confirm via PACER.
5. One reference I saw is internally garbled on the patent's own face — the NAPOLI-1 citation appears once as "NAPOL11" and the author as "von Hoff'D," and Carnevale & Ko appears once as "Zunevale J" (US11369597.pdf). These are OCR artifacts in the printed list, not separate references; I have interpreted them literally as the NAPOLI-1 and Carnevale/Ko documents respectively, but flag the spelling variance rather than silently correcting it.